Candid stewardship of one big open question: management engages seriously with a consequential unresolved outcome
The model's full reasoning — Q3 2016 call → NOWe need to determine if management identifies and seriously engages with one consequential operational outcome that is still unresolved. The call discusses loan growth, mortgage banking, solar tax credits, branch refresh, ATM initiatives. The most concrete is the branch refresh and ATM initiative. Peter Ho mentions: "On the business initiatives, John, those are going well. So a couple of projects afoot. One is the opportunity to increase our deposit penetration through our ATM fleet. We have refleeted our branches with envelope-free ATM machines. That initiative is going quite nicely. In fact last week I think we reached an all-time high point for us -- and the initiative is about a year and a half old now -- in terms of the percentage of people using the ATMs to make their deposits. Making good headway in our branch refresh project. Later this month we will -- actually next month -- be opening our Pearl City branch which we're pretty proud. That is a completely new format. Really the takeaway there is we have reduced the footprint by about one-third but increased the customer service space by a couple hundred feet. How we do that is obviously by pulling back on operations space that has really been rendered obsolete as a result of the digitization of a lot of our back office." This is a specific undertaking (branch refresh and ATM initiative) already in motion. Management discusses progress (all-time high ATM usage, opening new branch, reduced footprint) and what is going well. However, does management acknowledge uncertainty or unproven elements? They say "going quite nicely" and "making good headway" but do not explicitly mention risks or what could make it fail. They also mention "a lot of nice initiatives coming into the stream in the next year or so on our -- what I would say are our digital platforms." That is vague. The question asks for ONE consequential operational outcome that is still unresolved. The branch refresh is ongoing, but management does not treat it as genuinely open; they present it as successful. They don't discuss what is not yet proven or what could go wrong. They also don't explain actions to push it toward success beyond describing what they've done. The discussion is brief and positive, not with visible candor about difficulties. There is no mention of challenges or unproven aspects. So it's more of a routine update.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| MMLP | Martin Midstream Partners L.P. | Q2 2024 | 2024-07-18 | B |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| AKBA | Akebia Therapeutics, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DHX | DHI Group, Inc. | Q2 2017 | 2017-07-28 | D |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| FIBK | First Interstate BancSystem, Inc. | Q4 2016 | 2017-01-27 | B+ |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2016 | 2016-11-18 | D |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| SOHO | Sotherly Hotels Inc. | Q3 2016 | 2016-11-08 | D |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
TACT · Q4 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management seriously engaging with the large QSR rollout as a specific, already-in-motion undertaking whose outcome remains open. Bart describes it as an ongoing testing and implementation process that has taken over two years, with the company expecting it to begin rolling out in the second half of 2023 (mid-to end of Q3 through Q4) if testing succeeds. He notes recent new orders coming in during Q1, acknowledges the process has had “starts and stops,” and frames success around whether testing goes right and whether the pipeline continues to convert. Steve adds that the rollout will drive significant FST growth in 2024 2023. This is treated as genuinely uncertain rather than assured, with concrete operational details on current progress (new orders, testing), remaining risks (testing outcome, integration), and actions being taken (staying close to the customer, filling the pipeline).
FLUX · Q2 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management actively engaging with the unresolved outcome of scaling production to fulfill the record $31.4 million backlog while restoring gross margins, a specific undertaking already in motion through lean manufacturing, second-shift ramp (launching this month), Mexico sourcing, design cost reductions, and aggressive supplier negotiations. They describe concrete progress (weekly orders, production throughput improvements, quality initiatives) alongside acknowledged risks (chip and component shortages, delayed price effects, inventory commitments), explain current actions (vendor metrics, alternate suppliers, ERP changes), and outline success factors (higher-margin large-pack mix, reduced overstocking).
UAA · Q3 2017 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion... whose result is...YES The transcript shows management identifying the ERP system implementation (launched July 1) as a specific, already-in-motion operational outcome whose result remains unresolved. They detail concrete progress (system now stable, service levels improving) and current actions (ongoing change management with vendors and workforce, fine-tuning through Q4 into 2018), while openly noting residual impacts on shipments and productivity that will not fully resolve until later in the year. This is framed as a genuine risk to Q4 and full-year results rather than a guaranteed success, with visible operational specificity on what is working and what remains unproven.